{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:43:22Z","timestamp":1784004202165,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jphs.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T21:08:10Z","timestamp":1535317690000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"138","author":[{"given":"Yaozhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayun","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jphs.2018.08.008_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov Disord : Offic J Mov Disord Soc"},{"issue":"suppl 1","key":"10.1016\/j.jphs.2018.08.008_bib2","first-page":"24","article-title":"Oxidative mechanisms in nigral cell death in Parkinson's disease","volume":"13","author":"Jenner","year":"1998","journal-title":"Mov Disord : Offic J Mov Disord Soc"},{"issue":"9152","key":"10.1016\/j.jphs.2018.08.008_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(05)75631-2","article-title":"Parkinson's disease research moves on briskly","volume":"353","author":"Larkin","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jphs.2018.08.008_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1196\/annals.1427.023","article-title":"Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance","volume":"1147","author":"Zhou","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.jphs.2018.08.008_bib5","first-page":"17","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson's disease","volume":"106\u2013107","author":"Onyango","year":"2013","journal-title":"Prog Neurobiol"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2018.08.008_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijpharm.2011.10.039","article-title":"Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation","volume":"422","author":"Azeem","year":"2012","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.jphs.2018.08.008_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/mds.20435","article-title":"Levodopa in the treatment of Parkinson's disease: current controversies","volume":"20","author":"Gerlach","year":"2005","journal-title":"Mov Disord : official journal of the Movement Disorder Society"},{"issue":"3\u20134","key":"10.1016\/j.jphs.2018.08.008_bib8","first-page":"305","article-title":"Skin absorption enhancers","volume":"9","author":"Williams","year":"1992","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"16","key":"10.1016\/j.jphs.2018.08.008_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1359-6446(04)03180-0","article-title":"The transdermal revolution","volume":"9","author":"Thomas","year":"2004","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jphs.2018.08.008_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","article-title":"Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors","volume":"290","author":"Mierau","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jphs.2018.08.008_bib11","first-page":"141","article-title":"Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease","volume":"21","author":"Piercey","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"2\u20133","key":"10.1016\/j.jphs.2018.08.008_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(00)00853-3","article-title":"Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL\/6 mice","volume":"281","author":"Zou","year":"2000","journal-title":"Neurosci Lett"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2018.08.008_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0006-8993(96)00968-7","article-title":"Neuroprotective effects of the dopamine D2\/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons","volume":"742","author":"Hall","year":"1996","journal-title":"Brain Res"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2018.08.008_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(97)00075-9","article-title":"Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats","volume":"754","author":"Sethy","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.jphs.2018.08.008_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2015.10.023","article-title":"Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside in the MPTP-induced mouse model of Parkinson's disease: involvement of reactive oxygen species-mediated JNK, P38 and mitochondrial pathways","volume":"767","author":"He","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2018.08.008_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejphar.2015.09.029","article-title":"Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease","volume":"768","author":"Chen","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.jphs.2018.08.008_bib17","first-page":"35","article-title":"Mechanisms of MPTP toxicity","volume":"13","author":"Przedborski","year":"1998","journal-title":"Mov Disord Offic J Mov Disord Soc"},{"issue":"5985","key":"10.1016\/j.jphs.2018.08.008_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/311464a0","article-title":"Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism","volume":"311","author":"Markey","year":"1984","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jphs.2018.08.008_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","article-title":"The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease","volume":"991","author":"Przedborski","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.jphs.2018.08.008_bib20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease : mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"9680","key":"10.1016\/j.jphs.2018.08.008_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jphs.2018.08.008_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-Induced mouse model of Parkinson's disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2018.08.008_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"5\u20136","key":"10.1016\/j.jphs.2018.08.008_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.vph.2012.02.012","article-title":"Targeting NADPH oxidases in vascular pharmacology","volume":"56","author":"Schramm","year":"2012","journal-title":"Vasc Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2018.08.008_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11064-009-0035-4","article-title":"Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice","volume":"35","author":"Han","year":"2010","journal-title":"Neurochem Res"},{"issue":"12","key":"10.1016\/j.jphs.2018.08.008_bib26","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1089\/ars.2011.4400","article-title":"Insights into mitochondrial dysfunction: aging, amyloid-beta, and tau-A deleterious trio","volume":"16","author":"Schmitt","year":"2012","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.jphs.2018.08.008_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mcn.2012.11.011","article-title":"Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases","volume":"55","author":"Chaturvedi","year":"2013","journal-title":"Mol Cell Neurosci"},{"issue":"11","key":"10.1016\/j.jphs.2018.08.008_bib28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"Henchcliffe","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"3","key":"10.1016\/j.jphs.2018.08.008_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrn1868","article-title":"Expanding insights of mitochondrial dysfunction in Parkinson's disease","volume":"7","author":"Abou-Sleiman","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.1016\/j.jphs.2018.08.008_bib30","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1073\/pnas.051633998","article-title":"Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"98","author":"Vila","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.jphs.2018.08.008_bib31","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1073\/pnas.95.10.5789","article-title":"Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity","volume":"95","author":"Offen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jphs.2018.08.008_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"issue":"5517","key":"10.1016\/j.jphs.2018.08.008_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.292.5517.624","article-title":"The mitochondrion: is it central to apoptosis?","volume":"292","author":"Finkel","year":"2001","journal-title":"Science (New York, NY)"},{"issue":"9","key":"10.1016\/j.jphs.2018.08.008_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0962-8924(00)01803-1","article-title":"Mitochondria as the central control point of apoptosis","volume":"10","author":"Desagher","year":"2000","journal-title":"Trends Cell Biol"},{"issue":"47","key":"10.1016\/j.jphs.2018.08.008_bib35","doi-asserted-by":"crossref","first-page":"34479","DOI":"10.1074\/jbc.M705426200","article-title":"Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling","volume":"282","author":"Weng","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"31","key":"10.1016\/j.jphs.2018.08.008_bib36","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1021\/acs.jafc.8b02607","article-title":"Pinostrobin exerts neuroprotective actions in neurotoxin-induced Parkinson's disease models through Nrf2 induction","volume":"66","author":"Li","year":"2018","journal-title":"J\u00a0Agric Food Chem"},{"issue":"3","key":"10.1016\/j.jphs.2018.08.008_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/ars.2010.3363","article-title":"Mitochondrial ROS generation and its regulation: mechanisms involved in H(2)O(2) signaling","volume":"14","author":"Rigoulet","year":"2011","journal-title":"Antioxidants Redox Signal"},{"issue":"11","key":"10.1016\/j.jphs.2018.08.008_bib38","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1089\/ars.2010.3222","article-title":"Discovery of the negative regulator of Nrf2, Keap1: a historical overview","volume":"13","author":"Itoh","year":"2010","journal-title":"Antioxidants Redox Signal"},{"issue":"18","key":"10.1016\/j.jphs.2018.08.008_bib39","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1073\/pnas.172398899","article-title":"Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants","volume":"99","author":"Dinkova-Kostova","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.jphs.2018.08.008_bib40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.freeradbiomed.2004.02.075","article-title":"Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles","volume":"36","author":"Itoh","year":"2004","journal-title":"Free Radical Biol Med"},{"issue":"7","key":"10.1016\/j.jphs.2018.08.008_bib41","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1073\/pnas.0307301101","article-title":"Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers","volume":"101","author":"Wakabayashi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jphs.2018.08.008_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"17","key":"10.1016\/j.jphs.2018.08.008_bib43","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","article-title":"Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism","volume":"73","author":"Loboda","year":"2016","journal-title":"Cell Mol Life Sci : CMLS"},{"issue":"10","key":"10.1016\/j.jphs.2018.08.008_bib44","doi-asserted-by":"crossref","DOI":"10.2174\/1381612823666170113153818","article-title":"Synergistic interaction between heme oxygenase (HO) and nuclear-factor E2-related factor-2 (Nrf2) against oxidative stress in cardiovascular related diseases","volume":"23","author":"Ndisang","year":"2017","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.jphs.2018.08.008_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phymed.2017.11.007","article-title":"Seabuckthorn berry polysaccharide extracts protect against acetaminophen induced hepatotoxicity in mice via activating the Nrf-2\/HO-1-SOD-2 signaling pathway","volume":"38","author":"Wang","year":"2018","journal-title":"Phytomedicine : Int J Phytother Phytopharmacol"},{"issue":"17","key":"10.1016\/j.jphs.2018.08.008_bib46","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","article-title":"Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism","volume":"73","author":"Agnieszka","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.jphs.2018.08.008_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15061173","article-title":"Activation of the nrf2\/HO-1 signaling pathway contributes to the protective effects of sargassum serratifolium extract against oxidative stress-induced DNA damage and apoptosis in SW1353 human chondrocytes","volume":"15","author":"Park","year":"2018","journal-title":"Int J Environ Res Publ Health"},{"issue":"3","key":"10.1016\/j.jphs.2018.08.008_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/ars.2008.2242","article-title":"The Nrf2\/ARE pathway as a potential therapeutic target in neurodegenerative disease","volume":"11","author":"Calkins","year":"2009","journal-title":"Antioxidants Redox Signal"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861318301579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861318301579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:46:48Z","timestamp":1540212408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861318301579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1347861318301579"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2018.08.008","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}